-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Jointown issued an announcement saying that the company has undergone a number of personnel changes
.
Among them, Liu Yichang resigned from the position of general manager on April 23, 2022.
The reason for his departure was: due to personal reasons
.
It is understood that Liu Yichang has held this position in the company since November 5, 2020
.
After his departure, He Wei will assume the position of general manager on April 23, 2022
.
In addition, Lin Xinyang also resigned as the secretary of the board of directors on April 23, 2022.
The reason for his departure is: due to personal and work adjustment reasons
.
It is understood that Lin Xinyang has held this position in the company since November 16, 2011
.
After his departure, Liu Zhifeng will assume the position of secretary of the board of directors, and he will take office on April 23, 2022
.
In addition to Jointown, with the advancement of the new medical reform policy, the transformation and upgrading of the pharmaceutical industry has accelerated.
At present, many pharmaceutical companies in the pharmaceutical industry have frequent personnel turnover, and many companies have successively had core executives resign
.
For example, not long ago, Hengrui Pharmaceutical, the "first brother of medicine", issued an announcement saying that Zou Jianjun, the company's deputy general manager, applied for his resignation as the company's deputy general manager due to personal reasons
.
In fact, in the past year, Hengrui Medicine has had a total of 4 core executives resign, including 2 deputy general managers, 1 chairman, and 1 chief financial officer
.
Specifically, on February 25, 2022, Zhang Yuehong applied for his resignation as deputy general manager for personal reasons and no longer held any positions in the company
.
In November 2021, Zhou Song resigned from the position of Chief Financial Officer of Hengrui Medicine due to personal reasons
.
After resigning from the above positions, Zhou Song is still working in the company
.
In July 2021, Zhou Yunshu, the former chairman and general manager, resigned from the chairman and other positions due to physical reasons
.
Not long ago, AstraZeneca also issued an internal announcement: Lu Yanbin, the current deputy director of the Strategic Project Management Office, will leave the company to seek external development opportunities due to personal reasons
.
At the same time, Yu Qiran, the current new product planning and marketing director, will also serve as the head of the project management office of the general manager of oncology.
.
It is reported that in the past 10 months, AstraZeneca has actually had 10 executives leave, including general managers and vice presidents
.
Incomplete statistics show that in the first quarter of 2022, more than 120 senior executives from nearly 100 domestic pharmaceutical companies have resigned, including a large number of chairmen, general managers, deputy general managers, presidents, vice presidents, and core technicians
.
In this regard, analysts believe that "the resignation of pharmaceutical executives is closely related to the company's strategy to deal with the market environment
.
" Under the influence of factors such as centralized procurement and price reduction, industry prospects and performance tasks, after the relevant enterprise executives have been measured, they can only choose to resign
.
It is worth noting that the current statistics show that in the field of traditional Chinese medicine, a large number of people resign, and executives "leave the field" early.
It is likely that they feel great pressure on their own performance after the centralized procurement
.
With the current pharmaceutical market reform still in full swing, the industry predicts that with the vigorous development of the domestic innovative drug market, talents may become one of the important gaps for various pharmaceutical companies in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, Liu Yichang resigned from the position of general manager on April 23, 2022.
The reason for his departure was: due to personal reasons
.
It is understood that Liu Yichang has held this position in the company since November 5, 2020
.
After his departure, He Wei will assume the position of general manager on April 23, 2022
.
In addition, Lin Xinyang also resigned as the secretary of the board of directors on April 23, 2022.
The reason for his departure is: due to personal and work adjustment reasons
.
It is understood that Lin Xinyang has held this position in the company since November 16, 2011
.
After his departure, Liu Zhifeng will assume the position of secretary of the board of directors, and he will take office on April 23, 2022
.
In addition to Jointown, with the advancement of the new medical reform policy, the transformation and upgrading of the pharmaceutical industry has accelerated.
At present, many pharmaceutical companies in the pharmaceutical industry have frequent personnel turnover, and many companies have successively had core executives resign
.
For example, not long ago, Hengrui Pharmaceutical, the "first brother of medicine", issued an announcement saying that Zou Jianjun, the company's deputy general manager, applied for his resignation as the company's deputy general manager due to personal reasons
.
In fact, in the past year, Hengrui Medicine has had a total of 4 core executives resign, including 2 deputy general managers, 1 chairman, and 1 chief financial officer
.
Specifically, on February 25, 2022, Zhang Yuehong applied for his resignation as deputy general manager for personal reasons and no longer held any positions in the company
.
In November 2021, Zhou Song resigned from the position of Chief Financial Officer of Hengrui Medicine due to personal reasons
.
After resigning from the above positions, Zhou Song is still working in the company
.
In July 2021, Zhou Yunshu, the former chairman and general manager, resigned from the chairman and other positions due to physical reasons
.
Not long ago, AstraZeneca also issued an internal announcement: Lu Yanbin, the current deputy director of the Strategic Project Management Office, will leave the company to seek external development opportunities due to personal reasons
.
At the same time, Yu Qiran, the current new product planning and marketing director, will also serve as the head of the project management office of the general manager of oncology.
.
It is reported that in the past 10 months, AstraZeneca has actually had 10 executives leave, including general managers and vice presidents
.
Incomplete statistics show that in the first quarter of 2022, more than 120 senior executives from nearly 100 domestic pharmaceutical companies have resigned, including a large number of chairmen, general managers, deputy general managers, presidents, vice presidents, and core technicians
.
In this regard, analysts believe that "the resignation of pharmaceutical executives is closely related to the company's strategy to deal with the market environment
.
" Under the influence of factors such as centralized procurement and price reduction, industry prospects and performance tasks, after the relevant enterprise executives have been measured, they can only choose to resign
.
It is worth noting that the current statistics show that in the field of traditional Chinese medicine, a large number of people resign, and executives "leave the field" early.
It is likely that they feel great pressure on their own performance after the centralized procurement
.
With the current pharmaceutical market reform still in full swing, the industry predicts that with the vigorous development of the domestic innovative drug market, talents may become one of the important gaps for various pharmaceutical companies in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
